DNLI Earnings
Latest Revenue17.8M
Latest Net Income70.1M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q3 2026 | $0.37 | 17.8M | 70.1M | — | +150.0% |
| Q2 2026 | -$0.68 | 3.6M | -127553000 | — | +5.6% |
| Q1 2026 | -$0.69 | 0 | -128447000 | — | +11.5% |
| Q4 2025 | -$0.73 | 0 | -128549000 | — | -9.0% |
| Q3 2025 | -$0.74 | 0 | -126902000 | — | -17.5% |
| Q2 2025 | -$0.72 | 0 | -124119000 | — | -22.0% |
| Q1 2025 | -$0.78 | 0 | -132970000 | — | -14.7% |
| Q4 2024 | -$0.67 | 0 | -114753000 | — | +22.1% |
| Q3 2024 | -$0.63 | 0 | -107192000 | — | — |
| Q2 2024 | -$0.59 | 0 | -99026000 | — | — |
| Q1 2024 | -$0.68 | 0 | -101802000 | — | — |
| Q4 2023 | -$0.86 | 0 | -119473000 | — | — |
Denali Therapeutics (DNLI) — Earnings